Opinion|Videos|March 1, 2024
CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC
Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.
Advertisement
Episodes in this series
Advertisement
Related to this article
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
The top 5 OncLive TV videos of the week cover insights in renal cell carcinoma, HER2+ breast cancer, multiple myeloma, and chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
Surgeons, Medical Oncologists, and Radiation Oncologists Debate Current Thresholds for Systemic Therapy in EGFR-Mutated NSCLC
4
Zanubrutinib Plus R-BAP Elicits High Response Rates in Treatment-Naive Mantle Cell Lymphoma
5